Thymosin alpha 1: From bench to bedside

Annals of the New York Academy of Sciences

Volumn 1112, Issue , 2007, Pages 225-234

  Garaci, Enrico ^a   Favalli, Cartesio ^a   Pica, Francesca ^a   Vallebona, Paola Sinibaldi ^a   Palamara, Anna Teresa ^b   Matteucci, Claudia ^c   Pierimarchi, Pasquale ^c   Serafino, Annalucia ^c   Mastino, Antonio ^d   Bistoni, Francesco ^e   Romani, Luigina ^e   Rasi, Guido ^c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c CNR   (Italy)

^d UNIVERSITY OF MESSINA   (Italy)

^e UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Clinical trials; Preclinical models; Thymosin alpha 1

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; BETA INTERFERON; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE; INTERFERON; INTERLEUKIN 2; LAMIVUDINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEGINTERFERON; RIBAVIRIN; THYMOSIN ALPHA1; TOLL LIKE RECEPTOR;

ADVANCED CANCER; ANTIGEN EXPRESSION; BIOLOGICAL ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER MODEL; CANCER PATIENT; CELL ACTIVATION; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DENDRITIC CELL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ERYTHROLEUKEMIA; GENOTYPE; HEPATITIS B; HEPATITIS C; HUMAN; LEWIS CARCINOMA; LIVER METASTASIS; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MELANOMA B16; MUTANT; NONHUMAN; SIGNAL TRANSDUCTION;

ANIMALIA; HEPATITIS C VIRUS; MUS; RATTUS;

EID: 35349030180     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1415.044     Document Type: Conference Paper

References (26)

1. SCHULOF, R.S., M.J. LLOYD, J. STALLINGS, et al. 1985. Recombinant leukocyte A interferon in B-cell chronic lymphocytic leukemia: in vivo effects on autologous antitumor immunity. J. Biol. Response Mod. 4: 310-323.
2. GARACI, E., A. MASTINO, F. PICA, et al. 1990. Combination treatment using thymosin alpha 1 and interferon after cyclophosphamide is able to cure Lewis lung carcinoma in mice. Cancer Immunol. Immunother. 32: 154-160.
3. GARACI, E., F. PICA, A. MASTINO, et al. 1993. Antitumor effect of thymosin alpha 1/interleukin-2 or thymosin alpha 1/interferon alpha,beta following cyclophosphamide in mice injected with highly metastatic Friend erythroleukemia cells. J. Immunother. Emphasis Tumor Immunol. 13: 7-17.
4. PICA, F., M. FRASCHETTI, C. MATTEUCCI, et al. 1998. High doses of Thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma. Anticancer Res. 18(5A): 3571-3578.
5. RASI, G., G. SILECCHIA, P. SINIBALDI- VALLEBONA, et al. 1994. Anti-tumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-fluorouracil in liver metastases from colorectal cancer in rats. Int. J. Cancer 57: 701-705.
6. GIULIANI, C., G. NAPOLITANO, A. MASTINO, et al. 2000. Thymosin-alpha1 regulates MHC class I expression in FRTL-5 cells at transcriptional level. Eur. J. Immunol. 30: 778-786.
7. SINIBALDI VALLEBONA, P., P. PIERIMARCHI, G. MORONI, et al. 2002. Thymalfasin upregulates tumor antigen expression in colorectal cancer cells. ISOBM 23/S1/020-55.
8. GARACI, E., M. LOPEZ, G. BONSIGNORE, et al. 1995. Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin-alpha 1 and interferon-alpha 2a. Eur. J. Cancer 13/14: 2403-2405.
9. SALVATI, F., G. RASI, L. PORTALONE, et al. 1996. Combined treatment with thymosin alpha 1 and low dose interferon alpha after ifosfamide in non-small cell lung cancer: a phase II controlled trial. Anticancer Res. 16: 1001-1004.
10. RASI, G., E. TERZOLI, F. IZZO, et al. 2000. Combined treatment with thymosin-alpha1 and low dose interferon-alpha after dacarbazine in advanced melanoma. Melanoma Res. 10: 189-192.
11. GERIN, J.L., B.E. KORBA, P.J. COTE & B.C. TENNANT 1992. A preliminary report of a controlled study of thymosin alpha-1 in the woodchuck model of hepadnavirus infection. Adv. Exp. Med. Biol. 312: 121-123.
12. RASI, G., M.G. MUTCHNICK, D. DI VIRGILIO, et al. 1996. Combination of low-dose lymphoblastoid interferon and thymosin alpha-1 therapy in the treatment of chronic hepatitis B. J. Viral Hepat. 3: 191-196.
13. SARUC, M., H. YUCEYAR, N. KUCUKMETIN, et al. 2002. Combination thymosin-alpha 1 and interferon-alpha 2b in the treatment of anti-HBe positive chronic hepatitis B in Turkey. Hepatogastroenterology 49: 798-802.
14. SARUC, M., N. OZDEN, S. AYHAN, et al. 2003. Long-term outcomes of thymosin-alpha 1 and interferon alpha-2b combination therapy in patients with hepatitis B. 2003. J. Pharm. Sci. 92: 1386-1395.
15. CHAN, H.L., J.L. TANG, W. TAM & J.J. SUNG. 2001. The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis. Aliment Pharmacol. Ther. 15: 1899-1905.
16. ANDREONE, P., C. CURSARO, A. GRAMENZI, et al. 1996. A randomized controlled trial of thymosin-alpha 1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody - and hepatitis B virus DNA - positive chronic hepatitis B. Hepatology 24: 774-777.
17. ZHUANG, L., J. YOU, B.Z. TANG, et al. 2001. Preliminary results of hymosin-a1 versus interferon-alpha-treatment in patients with HBeAg negative and serum HBV DNA positive chronic hepatitis B. Word J. Gastroenterol. 7: 407-410.
18. YOU, J., L. ZHUANG, H.Y. CHENG, et al. 2006. Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: a randomized controlled study. World J. Gastroenterol. 12: 6715-6721.
19. IINO, S., J. TOYOTA, H. KUMADA, et al. 2005. The efficacy and safety of thymosin alpha-1 in Japanese patients with chronic hepatitis B; results from a randomized clinical trial. J. Viral Hepat. 12: 300-306.
20. RASI, G., M.G. MUTCHNICK, D. DI VIRGILIO, et al. 1996. Combination low-dose lymphoblastoid interferon and thymosin alpha 1 therapy in the treatment of chronic hepatitis B. J. Viral Hepat. 3: 191-196.
21. SHERMAN, K.E., M. SJOGREN, R.L. CREAGER, et al. 1998. Combination therapy with thymosin alpha 1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial. Hepatology 27: 1128-1135.
22. ANDREONE, P., A. GRAMENZI, C. CURSARO, et al. 2003. Interferon-alpha combined with ketoprofen as treatment of naive patients with chronic hepatitis C: a randomized controlled trial. J. Viral Hepat. 10: 306-309.
23. POO, J.L., F. SANCHEZ-AVILA, D. KERSHENOBICH, et al. 2004. Triple combination of thymalfasin, peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior interferon and ribavirin treatment: 24-week interim results of a pilot study. J. Gestroenterol. Hepatol. 6: S79-S81.
24. ROMANI, L., F. BISTONI, R. GAZIANO, et al. 2004. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood 103: 4232-4239.
25. ROMANI, L., F. BISTONI, K. PERRUCCIO, et al. 2006. Thymosin alpha1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. Blood 108: 2265-2274.
26. GARACI E., F. PICA, P. SINIBALDI- VALLEBONA, et al. 2003. Thymosin alpha 1 in combination with cytokines and chemotherapy for the treatment of cancer. Int. Immunopharmacol. 3: 1145-1150.